Page last updated: 2024-12-08
4,4,4-trifluorovaline
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4,4,4-trifluorovaline: RN refers to DL-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 259831 |
SCHEMBL ID | 189157 |
MeSH ID | M0421190 |
Synonyms (26)
Synonym |
---|
nsc-90439 |
nsc90439 |
16063-79-9 |
NCIOPEN2_001524 |
4,4,4-trifluorovaline |
2365-79-9 |
2-amino-4,4,4-trifluoro-3-methylbutanoic acid |
2-azanyl-4,4,4-tris(fluoranyl)-3-methyl-butanoic acid |
A810157 |
AKOS005257812 |
valine,4,4,4-trifluoro- |
4,4,4-trifluoro-dl-valine |
FT-0616978 |
SCHEMBL189157 |
mfcd00021721 |
J-009738 |
2-amino-3-trifluoromethylbutyric acid |
AKOS032963159 |
DTXSID20936352 |
2-amino-4,4,4-trifluoro-3-methylbutanoicacid |
AT29102 |
BS-27491 |
A878175 |
2-amino-3-methyl-4,4,4-trifluorobutanoic acid |
2-amino-3-methyl-4,4,4-trifluorobutyric acid |
CS-0320865 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |